From Wikipedia, the free encyclopedia
Chemical compound
Pipendoxifene
|
|
Other names | ERA-923 |
---|
|
2-(4-hydroxyphenyl)-3-methyl-1-[[4-(2-piperidin-1-ylethoxy)phenyl]methyl]indol-5-ol
|
CAS Number | |
---|
PubChem
CID | |
---|
ChemSpider | |
---|
UNII | |
---|
ChEMBL | |
---|
|
Formula | C29H32N2O3 |
---|
Molar mass | 456.586 g·mol−1 |
---|
3D model (
JSmol) | |
---|
CC1=C(N(C2=C1C=C(C=C2)O)CC3=CC=C(C=C3)OCCN4CCCCC4)C5=CC=C(C=C5)O
|
InChI=1S/C29H32N2O3/c1-21-27-19-25(33)11-14-28(27)31(29(21)23-7-9-24(32)10-8-23)20-22-5-12-26(13-6-22)34-18-17-30-15-3-2-4-16-30/h5-14,19,32-33H,2-4,15-18,20H2,1H3 Key:JICOGKJOQXTAIP-UHFFFAOYSA-N
|
Pipendoxifene (
INN) (developmental code name ERA-923) is a
nonsteroidal
selective estrogen receptor modulator (SERM) that was under development by
Ligand Pharmaceuticals and
Wyeth-Ayerst Laboratories (now Wyeth) for the treatment of
breast cancer but was not marketed.
[1]
[2]
[3] It is a member of the
2-phenylindole group of SERMs and is structurally related to
zindoxifene and the marketed
bazedoxifene.
[2]
[3] The drug reached
phase II
clinical trials before its development was discontinued.
[1]
[2] It was
synthesized at the same time as bazedoxifene and was intended as a backup drug for bazedoxifene, only to be developed further if bazedoxifene had failed in clinical trials.
[1]
[2] No further development was reported after 2002 and it was formally announced that development had been terminated in November 2005.
[1]
[4]
Unlike the SERM
raloxifene, pipendoxifene is devoid of
uterotrophic activity in immature/
ovariectomized rodents.
[3]
[5]
References
External links
|
---|
ERTooltip Estrogen receptor | Agonists |
- Steroidal:
2-Hydroxyestradiol
-
2-Hydroxyestrone
-
3-Methyl-19-methyleneandrosta-3,5-dien-17β-ol
-
3α-Androstanediol
-
3α,5α-Dihydrolevonorgestrel
-
3β,5α-Dihydrolevonorgestrel
-
3α-Hydroxytibolone
-
3β-Hydroxytibolone
-
3β-Androstanediol
-
4-Androstenediol
-
4-Androstenedione
-
4-Fluoroestradiol
-
4-Hydroxyestradiol
-
4-Hydroxyestrone
-
4-Methoxyestradiol
-
4-Methoxyestrone
-
5-Androstenediol
-
7-Oxo-DHEA
-
7α-Hydroxy-DHEA
-
7α-Methylestradiol
-
7β-Hydroxyepiandrosterone
-
8,9-Dehydroestradiol
-
8,9-Dehydroestrone
-
8β-VE2
-
10β,17β-Dihydroxyestra-1,4-dien-3-one (DHED)
-
11β-Chloromethylestradiol
-
11β-Methoxyestradiol
-
15α-Hydroxyestradiol
-
16-Ketoestradiol
-
16-Ketoestrone
-
16α-Fluoroestradiol
-
16α-Hydroxy-DHEA
-
16α-Hydroxyestrone
-
16α-Iodoestradiol
-
16α-LE2
-
16β-Hydroxyestrone
-
16β,17α-Epiestriol (16β-hydroxy-17α-estradiol)
-
17α-Estradiol (
alfatradiol)
-
17α-Dihydroequilenin
-
17α-Dihydroequilin
-
17α-Epiestriol (16α-hydroxy-17α-estradiol)
-
17α-Ethynyl-3α-androstanediol
-
17α-Ethynyl-3β-androstanediol
-
17β-Dihydroequilenin
-
17β-Dihydroequilin
-
17β-Methyl-17α-dihydroequilenin
-
Abiraterone
-
Abiraterone acetate
-
Alestramustine
-
Almestrone
-
Anabolic steroids (e.g.,
testosterone and
esters,
methyltestosterone,
metandienone (methandrostenolone),
nandrolone and
esters, many others; via estrogenic metabolites)
-
Atrimustine
-
Bolandiol
-
Bolandiol dipropionate
-
Butolame
-
Clomestrone
-
Cloxestradiol
-
Conjugated estriol
-
Conjugated estrogens
-
Cyclodiol
-
Cyclotriol
-
DHEA
-
DHEA-S
-
ent-Estradiol
-
Epiestriol (16β-epiestriol, 16β-hydroxy-17β-estradiol)
-
Epimestrol
-
Equilenin
-
Equilin
-
ERA-63 (ORG-37663)
-
Esterified estrogens
-
Estetrol
-
Estradiol
-
Estramustine
-
Estramustine phosphate
-
Estrapronicate
-
Estrazinol
-
Estriol
-
Estrofurate
-
Estrogenic substances
-
Estromustine
-
Estrone
-
Etamestrol (eptamestrol)
-
Ethinylandrostenediol
-
Ethinylestradiol
-
Ethinylestriol
-
Ethylestradiol
-
Etynodiol
-
Etynodiol diacetate
-
Hexolame
-
Hippulin
-
Hydroxyestrone diacetate
-
Lynestrenol
-
Lynestrenol phenylpropionate
-
Mestranol
-
Methylestradiol
-
Moxestrol
-
Mytatrienediol
-
Nilestriol
-
Norethisterone
-
Noretynodrel
-
Orestrate
-
Pentolame
-
Prodiame
-
Prolame
-
Promestriene
-
RU-16117
-
Quinestradol
-
Quinestrol
-
Tibolone
- Xenoestrogens:
Anise-related (e.g.,
anethole,
anol,
dianethole,
dianol,
photoanethole)
-
Chalconoids (e.g.,
isoliquiritigenin,
phloretin,
phlorizin (phloridzin),
wedelolactone)
-
Coumestans (e.g.,
coumestrol,
psoralidin)
-
Flavonoids (incl.
7,8-DHF,
8-prenylnaringenin,
apigenin,
baicalein,
baicalin,
biochanin A,
calycosin,
catechin,
daidzein,
daidzin,
ECG,
EGCG,
epicatechin,
equol,
formononetin,
glabrene,
glabridin,
genistein,
genistin,
glycitein,
kaempferol,
liquiritigenin,
mirificin,
myricetin,
naringenin,
penduletin,
pinocembrin,
prunetin,
puerarin,
quercetin,
tectoridin,
tectorigenin)
-
Lavender oil
-
Lignans (e.g.,
enterodiol,
enterolactone,
nyasol (cis-hinokiresinol))
-
Metalloestrogens (e.g.,
cadmium)
-
Pesticides (e.g.,
alternariol,
dieldrin,
endosulfan,
fenarimol,
HPTE,
methiocarb,
methoxychlor,
triclocarban,
triclosan)
-
Phytosteroids (e.g.,
digitoxin (
digitalis),
diosgenin,
guggulsterone)
-
Phytosterols (e.g.,
β-sitosterol,
campesterol,
stigmasterol)
-
Resorcylic acid lactones (e.g.,
zearalanone,
α-zearalenol,
β-zearalenol,
zearalenone,
zeranol (α-zearalanol),
taleranol (teranol, β-zearalanol))
-
Steroid-like (e.g.,
deoxymiroestrol,
miroestrol)
-
Stilbenoids (e.g.,
resveratrol,
rhaponticin)
-
Synthetic xenoestrogens (e.g.,
alkylphenols,
bisphenols (e.g.,
BPA,
BPF,
BPS),
DDT,
parabens,
PBBs,
PHBA,
phthalates,
PCBs)
- Others (e.g.,
agnuside,
rotundifuran)
|
---|
Mixed (
SERMsTooltip Selective estrogen receptor modulators) | |
---|
Antagonists |
- Coregulator-binding modulators:
ERX-11
|
---|
|
---|
GPERTooltip G protein-coupled estrogen receptor | Agonists | |
---|
Antagonists | |
---|
Unknown | |
---|
|
---|
|